Bulk Pharmaceutical API Sources for LOZOL

Bulk Pharmaceutical API Sources for LOZOL

Vendor	Vendor Homepage	Vendor Sku	API Url
TCI (Tokyo Chemical Industry)		I0730
Molport		MolPort-003-666-209
Hangzhou APIChem Technology		AC-2073

Bulk Active Pharmaceutical Ingredient (API) Sources for LOZOL

Last updated: February 19, 2026

This report analyzes the global landscape of bulk active pharmaceutical ingredient (API) suppliers for LOZOL (indapamide), a diuretic medication. The analysis focuses on identifying key manufacturers, their production capabilities, regulatory compliance, and potential supply chain risks.

What is LOZOL (Indapamide)?

LOZOL is a thiazide-like diuretic used to treat high blood pressure and fluid retention (edema) associated with conditions like heart failure. It works by increasing the excretion of sodium and water by the kidneys. The primary active pharmaceutical ingredient is indapamide.

Global Indapamide API Manufacturing Landscape

The production of indapamide API is concentrated among a limited number of manufacturers, primarily in Asia. Key manufacturing hubs include India and China, with some presence in Europe. These manufacturers vary in scale, regulatory adherence, and product quality.

Major Indapamide API Manufacturers

Manufacturer Name	Country of Origin	Key Certifications	Reported Production Capacity (Metric Tons/Year)	Notes
Lupin Limited	India	US FDA, EU GMP, WHO-GMP	Not Disclosed	Significant global pharmaceutical player with API division.
Torrent Pharmaceuticals	India	US FDA, EU GMP	Not Disclosed	Established Indian pharmaceutical company.
Aurobindo Pharma	India	US FDA, EU GMP, PMDA (Japan)	Not Disclosed	Diversified API and finished dosage form manufacturer.
Dr. Reddy's Laboratories	India	US FDA, EU GMP	Not Disclosed	Broad portfolio of APIs.
Zhejiang Huahai Pharmaceutical	China	US FDA, EU GMP, PMDA (Japan), KFDA (Korea)	Not Disclosed	Large-scale API producer.
Jiangsu Hengrui Medicine	China	US FDA, EU GMP	Not Disclosed	Focus on research and development alongside manufacturing.
Siegfried AG	Switzerland	US FDA, EU GMP, Swissmedic	Not Disclosed	European manufacturer with a focus on complex APIs.

Source: Manufacturer websites, industry reports, regulatory filings (specific capacities are often proprietary and not publicly disclosed).

Regulatory Compliance and Quality Standards

API manufacturers must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy. Key compliance aspects include:

• Good Manufacturing Practices (GMP): Adherence to GMP guidelines, as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), is essential.
• Drug Master Files (DMFs): Manufacturers typically maintain DMFs submitted to regulatory agencies. These documents contain detailed information about the manufacturing process, quality control, and stability of the API.
• Inspections: Regular inspections by regulatory authorities are critical. Manufacturers with a history of successful inspections by major agencies (US FDA, EMA, PMDA) are generally preferred.
• Pharmacopoeia Compliance: APIs must meet the standards outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.).

US FDA Inspection History (Indapamide API Manufacturers)

While specific inspection reports for indapamide API production are not publicly detailed, a manufacturer's overall US FDA inspection record is indicative of their compliance. Companies like Lupin, Torrent Pharma, Aurobindo Pharma, Dr. Reddy's Laboratories, and Zhejiang Huahai Pharmaceutical have had various facilities inspected by the US FDA for different APIs. A history of Form 483 observations or warning letters can signify potential quality issues or compliance gaps.

EU GMP Certification

European Union Good Manufacturing Practice (EU GMP) certification is a prerequisite for APIs intended for the EU market. Manufacturers listed above, particularly those in India and China, commonly obtain EU GMP certification for their API facilities.

Supply Chain Considerations and Risk Factors

Sourcing indapamide API involves several considerations:

Geopolitical Risks

• Concentration of Manufacturing: The heavy reliance on India and China for API manufacturing presents geopolitical risks. Trade disputes, export restrictions, or political instability in these regions can disrupt supply chains.
• Logistics and Transportation: Global shipping challenges, including freight costs, port congestion, and transit times, impact the timely delivery of APIs.

Quality and Compliance Risks

• Variable Quality Standards: While major manufacturers adhere to international standards, smaller or less-regulated producers may have inconsistent quality. Due diligence and rigorous supplier qualification are crucial.
• Recalls and Contamination: Past incidents of API contamination or recalls by major manufacturers highlight the importance of robust quality control systems and supply chain transparency.

Economic Factors

• Price Volatility: API prices can fluctuate based on raw material costs, manufacturing efficiency, and market demand.
• Currency Fluctuations: For international procurement, currency exchange rates can impact the final cost of the API.

Key Takeaways

The global market for indapamide API is dominated by manufacturers in India and China. Key suppliers possess significant regulatory certifications, including US FDA and EU GMP. Companies considering indapamide API procurement should prioritize suppliers with a strong track record of quality, regulatory compliance, and transparent supply chain management. Geopolitical stability, logistical efficiency, and robust quality assurance protocols are critical for mitigating supply chain risks.

Frequently Asked Questions

1. Which countries are the primary sources for indapamide API?

India and China are the principal manufacturing locations for indapamide API.

2. What are the key regulatory bodies that oversee indapamide API manufacturing?

The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan are key regulatory bodies.

3. How can a company ensure the quality of indapamide API from a new supplier?

Thorough supplier qualification, including site audits, review of quality agreements, verification of regulatory certifications, and independent testing of API batches, is essential.

4. What is the role of Drug Master Files (DMFs) in API sourcing?

DMFs provide regulatory authorities with confidential detailed information about the manufacturing, processing, packaging, and storing of the API, facilitating the drug approval process for finished dosage forms.

5. Are there any significant supply chain vulnerabilities specific to indapamide API?

The primary vulnerability lies in the geographic concentration of manufacturing, making the supply chain susceptible to geopolitical events or trade disruptions affecting major producing regions like India and China.

Citations

[1] Lupin Limited. (n.d.). API Business. Retrieved from https://www.lupin.com/our-business/api-business/ [2] Torrent Pharmaceuticals Ltd. (n.d.). API. Retrieved from https://www.torrentpharma.com/business/api/ [3] Aurobindo Pharma Limited. (n.d.). Active Pharmaceutical Ingredients (APIs). Retrieved from https://www.aurobindo.com/products-services/api/ [4] Dr. Reddy's Laboratories. (n.d.). APIs. Retrieved from https://www.drreddys.com/our-business/apicompany/ [5] Zhejiang Huahai Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from http://www.huahaipharm.com/products/ [6] Jiangsu Hengrui Medicine Co., Ltd. (n.d.). API. Retrieved from https://www.hengrui.com/en/api [7] Siegfried AG. (n.d.). APIs. Retrieved from https://www.siegfried.ch/en/products-services/apis/